Musab M. A. Omar

RMIT University AU

0000-0002-3661-2581

Publications

Citations

H-Index

i10-Index

1.5

2yr Mean Cite

True

Cite/Paper

Data combined from OpenAlex + Semantic Scholar. OA = OpenAlex S2 = Semantic Scholar

Verify on Google Scholar

Publication & Citation Trends

Publications

0 total

Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?

Musab M. A. Omar, Majed A Alanazi, D. Jackson - Hematology, Transfusion and Cell Therapy, 2026

Cited by 0 Semantic Scholar

Efficacy and challenges involving combination therapies in CLL. OA

Majed Alanazi, Faith A. A. Kwa, Musab M. A. Omar, Juliana Antonipillai, Denise E. Jackson - Drug Discovery Today, 2024

Cited by 3 Semantic Scholar

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans. OA

G. Dobie, Fahd A. Kuriri, Musab M. A. Omar, Fehaid Alanazi, Ali M. Gazwani - Blood Advances, 2019

Cited by 52 Semantic Scholar

Research Topics

Chronic Lymphocytic Leukemia Research (2) Lymphoma Diagnosis and Treatment (1) Lung Cancer Treatments and Mutations (1) Platelet Disorders and Treatments (1) Chronic Myeloid Leukemia Treatments (1)

Affiliations

RMIT University

AU 2026 - 2019

External Profiles

OpenAlex Profile Semantic Scholar Profile ORCID Profile Google Scholar

Share Profile

Back to Researchers

Musab M. A. Omar

Publication & Citation Trends

Publications

Is asciminib an effective tyrosine kinase inhibitor for chronic myeloid leukemia patients with tyrosine kinase inhibitor resistance?

Efficacy and challenges involving combination therapies in CLL. OA

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans. OA

Research Topics

Affiliations

External Profiles

Share Profile

Journal Details

Join JournalsHub

Welcome Back